NASDAQ:ASND Ascendis Pharma A/S (ASND) Stock Price, News & Analysis $251.27 0.00 (0.00%) Closing price 10/30/2026 04:00 PM EasternExtended Trading$258.25 +6.98 (+2.78%) As of 05:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Ascendis Pharma A/S Stock (NASDAQ:ASND) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ascendis Pharma A/S alerts:Sign Up Key Stats Today's Range$249.55▼$255.6150-Day Range$222.69▼$271.1252-Week Range$188.07▼$282.15Volume386,694 shsAverage Volume694,922 shsMarket Capitalization$15.67 billionP/E Ratio19.49Dividend YieldN/APrice Target$305.95Consensus RatingModerate Buy Company Overview Ascendis Pharma A/S is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve treatment convenience, maintain controlled drug exposure, and address unmet medical needs. Its commercial products include SKYTROFA (lonapegsomatropin-tcgd), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a once-daily therapy for adults with hypoparathyroidism. SKYTROFA is marketed in the United States and other markets, while YORVIPATH has received approval in the United States. Ascendis also maintains a development pipeline spanning endocrinology, rare diseases, and other therapeutic areas, including investigational treatments based on its TransCon platform. The company was founded in Denmark and has corporate operations in Copenhagen and the United States. Jan Mikkelsen serves as president and chief executive officer.AI Generated. May Contain Errors. Read More Ascendis Pharma A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks96th Percentile Overall ScoreASND MarketRank™: 4.792891676465 of 5 starsAscendis Pharma A/S scored higher than 96% of companies evaluated by MarketBeat, and ranked 10th out of 894 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingAscendis Pharma A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on no strong buy ratings, 19 buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialAscendis Pharma A/S has a consensus price target of $305.95, representing about 21.8% upside from its current price of $251.27.Amount of Analyst CoverageAscendis Pharma A/S has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ascendis Pharma A/S's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth159.48% Earnings GrowthEarnings for Ascendis Pharma A/S are expected to grow by 159.48% in the coming year, from $3.43 to $8.90 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ascendis Pharma A/S is 19.49, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.93.Price to Earnings Ratio vs. SectorThe P/E ratio of Ascendis Pharma A/S is 19.49, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.80.Read more about Ascendis Pharma A/S's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.37% of the float of Ascendis Pharma A/S has been sold short.Short Interest Ratio / Days to CoverAscendis Pharma A/S has a short interest ratio ("days to cover") of 4.15.Change versus previous monthShort interest in Ascendis Pharma A/S has recently decreased by 10.09%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAscendis Pharma A/S does not currently pay a dividend.Dividend GrowthAscendis Pharma A/S does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.89 News SentimentAscendis Pharma A/S has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Ascendis Pharma A/S this week, compared to 6 articles on an average week.Search InterestOnly 6 people have searched for ASND on MarketBeat in the last 30 days. This is a decrease of -65% compared to the previous 30 days.MarketBeat Follows6 people have added Ascendis Pharma A/S to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ascendis Pharma A/S insiders have sold 64.53% more of their company's stock than they have bought. Specifically, they have bought $492,660.00 in company stock and sold $810,570.00 in company stock.Percentage Held by Insiders40.00% of the stock of Ascendis Pharma A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsAscendis Pharma A/S has minimal institutional ownership at this time.Read more about Ascendis Pharma A/S's insider trading history. Receive ASND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ASND Stock News HeadlinesAscendis Pharma A/S (NASDAQ:ASND) Stock Gets Downgrade from Wall Street Zen4 hours ago | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Upgraded at Canaccord Genuity GroupOctober 29, 2026 | americanbankingnews.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.November 2 at 1:00 AM | Weiss Ratings (Ad)Morgan Stanley Sticks to Their Buy Rating for Ascendis Pharma (ASND)October 28, 2026 | theglobeandmail.comAscendis Pharma A/S announces TransCon PTH pooled data showing kidney function improvements for up to 5 yearsOctober 26, 2026 | msn.comTransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 YearsOctober 26, 2026 | markets.businessinsider.comAscendis Pharma Says Trial Results Show 'Meaningful Improvements' in Kidney Function in Adults with HypoparathyroidismOctober 26, 2026 | marketscreener.comMAscendis Pharma A/S Receives Positive CHMP Opinion Recommending Marketing Authorization For Once-Weekly TransCon CNP For The Treatment Of Achondroplasia In ChildrenOctober 17, 2026 | marketscreener.comMSee More Headlines ASND Stock Analysis - Frequently Asked Questions How have ASND shares performed this year? Ascendis Pharma A/S's stock was trading at $213.24 at the beginning of the year. Since then, ASND stock has increased by 17.8% and is now trading at $251.27. How were Ascendis Pharma A/S's earnings last quarter? Ascendis Pharma A/S (NASDAQ:ASND) posted its earnings results on Friday, August, 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.71 by $0.68. The biotechnology company earned $387.22 million during the quarter, compared to analysts' expectations of $376.75 million. Ascendis Pharma A/S had a trailing twelve-month return on equity of 32.54% and a net margin of 70.99%. Read the conference call transcript. When did Ascendis Pharma A/S IPO? Ascendis Pharma A/S (ASND) raised $85 million in an initial public offering on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager. Who are Ascendis Pharma A/S's major shareholders? Top institutional shareholders of Ascendis Pharma A/S include Sapient Capital LLC (0.15%), Henry James International Management Inc. (0.03%), Assenagon Asset Management S.A. (0.03%) and China Universal Asset Management Co. Ltd.. Insiders that own company stock include Scott Thomas Smith, Mads Bodenhoff, Jean Jacques Bienaime and Flemming Steen Jensen. View institutional ownership trends. How do I buy shares of Ascendis Pharma A/S? Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ascendis Pharma A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ascendis Pharma A/S investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Broadcom (AVGO), CrowdStrike (CRWD), AbbVie (ABBV) and Alibaba Group (BABA). Company Calendar Last Earnings8/14/2026Today11/01/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, ASND's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ASND CIK1612042 Webwww.ascendispharma.com Phone(457) 022-2244Fax45-3694-4010Employees1,189Year Founded2007Price Target and Rating Average Price Target for Ascendis Pharma A/S$305.95 High Price Target$344.00 Low Price Target$255.00 Potential Upside/Downside+21.8%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage21 Analysts Profitability EPS (Trailing Twelve Months)$12.89 Trailing P/E Ratio19.49 Forward P/E Ratio73.26 P/E GrowthN/ANet Income-$258 million Net Margins70.99% Pretax Margin8.92% Return on Equity32.54% Return on Assets7.71% Debt Debt-to-Equity Ratio0.27 Current Ratio2.99 Quick Ratio2.32 Sales & Book Value Annual Sales$1.05 billion Price / Sales14.97 Cash FlowN/A Price / Cash FlowN/A Book Value($2.97) per share Price / Book-84.60Miscellaneous Outstanding Shares62,377,000Free Float37,426,000Market Cap$15.67 billion OptionableOptionable Beta0.38 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ASND) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredDoes your nest egg have an expiration date?A $250,000 nest egg growing at 5% a year and paying out $2,500 a month runs dry in just over a decade. Start w...Investors Alley | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredElon says the ‘S’ wordElon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men d...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascendis Pharma A/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
